Rapid infusion rituximab is well tolerated in patients with primary CNS lymphoma

AIM: To establish the safety and feasibility of rapidly infusing rituximab over 90 min in patients with primary CNS lymphoma (PCNSL). PATIENTS & METHODS: We retrospectively reviewed all patients with PCNSL who received rapid rituximab infusions (RRI) from January 2016 to January 2017. Primary en...

Descripción completa

Detalles Bibliográficos
Autores principales: Modelevsky, Lisa, Tizon, Richard, Reiss, Samantha N, Smith, Marcel, Garonce, Rachel, Kaley, Thomas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Future Medicine Ltd 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6200062/
https://www.ncbi.nlm.nih.gov/pubmed/30221993
http://dx.doi.org/10.2217/cns-2018-0001
_version_ 1783365265522688000
author Modelevsky, Lisa
Tizon, Richard
Reiss, Samantha N
Smith, Marcel
Garonce, Rachel
Kaley, Thomas
author_facet Modelevsky, Lisa
Tizon, Richard
Reiss, Samantha N
Smith, Marcel
Garonce, Rachel
Kaley, Thomas
author_sort Modelevsky, Lisa
collection PubMed
description AIM: To establish the safety and feasibility of rapidly infusing rituximab over 90 min in patients with primary CNS lymphoma (PCNSL). PATIENTS & METHODS: We retrospectively reviewed all patients with PCNSL who received rapid rituximab infusions (RRI) from January 2016 to January 2017. Primary end point was incidence of infusion reactions. RESULTS & CONCLUSION: 11 patients received a total of 44 RRIs. Rituximab was dosed at 500 or 750 mg/m(2). Premedication included acetaminophen and diphenhydramine. No infusion reactions occurred during any RRI. Two infusions were administered with steroids for neurologic symptoms at baseline (4.5%). Rapid administration of rituximab was safe and feasible for patients with PCNSL and at the higher doses received.
format Online
Article
Text
id pubmed-6200062
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Future Medicine Ltd
record_format MEDLINE/PubMed
spelling pubmed-62000622018-10-26 Rapid infusion rituximab is well tolerated in patients with primary CNS lymphoma Modelevsky, Lisa Tizon, Richard Reiss, Samantha N Smith, Marcel Garonce, Rachel Kaley, Thomas CNS Oncol Research Article AIM: To establish the safety and feasibility of rapidly infusing rituximab over 90 min in patients with primary CNS lymphoma (PCNSL). PATIENTS & METHODS: We retrospectively reviewed all patients with PCNSL who received rapid rituximab infusions (RRI) from January 2016 to January 2017. Primary end point was incidence of infusion reactions. RESULTS & CONCLUSION: 11 patients received a total of 44 RRIs. Rituximab was dosed at 500 or 750 mg/m(2). Premedication included acetaminophen and diphenhydramine. No infusion reactions occurred during any RRI. Two infusions were administered with steroids for neurologic symptoms at baseline (4.5%). Rapid administration of rituximab was safe and feasible for patients with PCNSL and at the higher doses received. Future Medicine Ltd 2018-09-17 /pmc/articles/PMC6200062/ /pubmed/30221993 http://dx.doi.org/10.2217/cns-2018-0001 Text en © 2018 Lisa Modelevsky This work is licensed under a Creative Commons Attribution 4.0 License (http://creativecommons.org/licenses/by/4.0/)
spellingShingle Research Article
Modelevsky, Lisa
Tizon, Richard
Reiss, Samantha N
Smith, Marcel
Garonce, Rachel
Kaley, Thomas
Rapid infusion rituximab is well tolerated in patients with primary CNS lymphoma
title Rapid infusion rituximab is well tolerated in patients with primary CNS lymphoma
title_full Rapid infusion rituximab is well tolerated in patients with primary CNS lymphoma
title_fullStr Rapid infusion rituximab is well tolerated in patients with primary CNS lymphoma
title_full_unstemmed Rapid infusion rituximab is well tolerated in patients with primary CNS lymphoma
title_short Rapid infusion rituximab is well tolerated in patients with primary CNS lymphoma
title_sort rapid infusion rituximab is well tolerated in patients with primary cns lymphoma
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6200062/
https://www.ncbi.nlm.nih.gov/pubmed/30221993
http://dx.doi.org/10.2217/cns-2018-0001
work_keys_str_mv AT modelevskylisa rapidinfusionrituximabiswelltoleratedinpatientswithprimarycnslymphoma
AT tizonrichard rapidinfusionrituximabiswelltoleratedinpatientswithprimarycnslymphoma
AT reisssamanthan rapidinfusionrituximabiswelltoleratedinpatientswithprimarycnslymphoma
AT smithmarcel rapidinfusionrituximabiswelltoleratedinpatientswithprimarycnslymphoma
AT garoncerachel rapidinfusionrituximabiswelltoleratedinpatientswithprimarycnslymphoma
AT kaleythomas rapidinfusionrituximabiswelltoleratedinpatientswithprimarycnslymphoma

Ejemplares similares